These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23710206)

  • 1. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain.
    Maes W; Verschuere T; Van Hoylandt A; Boon L; Van Gool S
    Clin Dev Immunol; 2013; 2013():952469. PubMed ID: 23710206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.
    El Andaloussi A; Han Y; Lesniak MS
    J Neurosurg; 2006 Sep; 105(3):430-7. PubMed ID: 16961139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
    Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
    J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
    Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
    Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.
    Dey M; Chang AL; Miska J; Wainwright DA; Ahmed AU; Balyasnikova IV; Pytel P; Han Y; Tobias A; Zhang L; Qiao J; Lesniak MS
    J Immunol; 2015 Jul; 195(1):367-76. PubMed ID: 26026061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.
    McFarland BC; Marks MP; Rowse AL; Fehling SC; Gerigk M; Qin H; Benveniste EN
    Oncotarget; 2016 Apr; 7(15):20621-35. PubMed ID: 26967393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
    Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
    J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of central and peripheral immunomodulation in a murine glioma model.
    Kennedy BC; Maier LM; D'Amico R; Mandigo CE; Fontana EJ; Waziri A; Assanah MC; Canoll P; Anderson RC; Anderson DE; Bruce JN
    BMC Immunol; 2009 Feb; 10():11. PubMed ID: 19226468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.
    Zhang B; Jia H; Liu J; Yang Z; Jiang T; Tang K; Li D; Huang C; Ma J; Shen GX; Ye D; Huang B
    J Immunol; 2010 Dec; 185(12):7199-206. PubMed ID: 21068404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
    Kosaka A; Ohkuri T; Okada H
    Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment.
    Cantini G; Pisati F; Mastropietro A; Frattini V; Iwakura Y; Finocchiaro G; Pellegatta S
    Cancer Immunol Immunother; 2011 Dec; 60(12):1739-50. PubMed ID: 21779877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
    Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF
    Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas.
    Graf MR; Sauer JT; Merchant RE
    J Neurooncol; 2005 May; 73(1):29-36. PubMed ID: 15933813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.
    Panek WK; Toedebusch RG; Mclaughlin BE; Dickinson PJ; Van Dyke JE; Woolard KD; Berens ME; Lesniak MS; Sturges BK; Vernau KM; Li C; Miska J; Toedebusch CM
    J Neurooncol; 2024 Sep; 169(3):647-658. PubMed ID: 39046599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.
    Panek WK; Pituch KC; Miska J; Kim JW; Rashidi A; Kanojia D; Lopez-Rosas A; Han Y; Yu D; Chang CL; Kane JR; Zhang P; Cordero A; Lesniak MS
    Mol Neurobiol; 2019 Jul; 56(7):5032-5040. PubMed ID: 30460615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
    Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
    Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics.
    Umemura N; Saio M; Suwa T; Kitoh Y; Bai J; Nonaka K; Ouyang GF; Okada M; Balazs M; Adany R; Shibata T; Takami T
    J Leukoc Biol; 2008 May; 83(5):1136-44. PubMed ID: 18285406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model.
    Jia W; Jackson-Cook C; Graf MR
    J Neuroimmunol; 2010 Jun; 223(1-2):20-30. PubMed ID: 20452681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.